FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911637802> ?p ?o ?g. }

• W2911637802 endingPage "688" @default.
• W2911637802 startingPage "688" @default.
• W2911637802 abstract "688 Background: BRAF V600E mutation occurs in 10%-–15% of patients (pts) with mCRC and confers a poor prognosis. After first-line therapy, standard second-line therapies provide limited benefit, with objective response rates (ORRs) < 10%, and overall survival (OS) of 4–6 months (mo). BEACON CRC (NCT02928224) is a 3-arm phase 3 trial of triplet therapy with the BRAF inhibitor ENCO + MEK inhibitor BINI + anti–EGFR antibody CETUX vs ENCO + CETUX vs a control arm (irinotecan/FOLFIRI + CETUX) in pts with BRAF V600E mCRC in the second or third-line setting. A safety lead-in (SLI) of the triplet therapy was conducted in 30 pts prior to initiation of the randomized part of the trial. Previously reported confirmed ORR in 29 pts with BRAF V600E mCRC was 48% and median progression-free survival (PFS) was 8.0 mo (Van Cutsem E, et al. Ann Oncol. 2018;29:O-027). Here we present updated safety and efficacy results including mature OS. Methods: All pts in the SLI received ENCO 300 mg once daily + BINI 45 mg twice daily + CETUX standard weekly dose. Assessments included efficacy (ORR, duration of response, time to response, PFS, and OS), safety, and tolerability. Results: Among 30 pts treated, 1 had a BRAF non-V600E mutation and is not included in the efficacy analyses. At data cutoff, the median follow-up time for survival was 18.2 mo and median exposure was 7.8 mo (range 0.5–21.4 mo). The confirmed ORR and median PFS remain unchanged from the previous report (ORR, 48% [95%CI, 29.4–67.5]; PFS, 8.0 mo [95% CI, 5.6–9.3 mo]). Mature median OS is 15.3 mo (95% CI, 9.6 mo–not reached). The triplet continues to be well-tolerated with no unexpected toxicities. The most common grade 3/4 toxicities were fatigue (13%), anemia, increases in creatine phosphokinase and/or aspartate aminotransferase, and urinary tract infections (each 10%). The rate of grade 3/4 skin toxicities continues to be lower than generally observed with CETUX in mCRC. Conclusions: With longer follow-up, triplet therapy with ENCO + BINI + CETUX continues to be well tolerated. Median PFS and now mature median OS are substantially improved over historical data for current standard-of-care options. Clinical trial information: NCT02928224." @default.
• W2911637802 created "2019-02-21" @default.
• W2911637802 creator A5000418012 @default.
• W2911637802 creator A5004259329 @default.
• W2911637802 creator A5005460328 @default.
• W2911637802 creator A5015509025 @default.
• W2911637802 creator A5024390084 @default.
• W2911637802 creator A5030657436 @default.
• W2911637802 creator A5038339239 @default.
• W2911637802 creator A5040469092 @default.
• W2911637802 creator A5041301470 @default.
• W2911637802 creator A5043177546 @default.
• W2911637802 creator A5057458005 @default.
• W2911637802 creator A5061200817 @default.
• W2911637802 creator A5062748030 @default.
• W2911637802 creator A5063738443 @default.
• W2911637802 creator A5069877747 @default.
• W2911637802 creator A5072066227 @default.
• W2911637802 creator A5078038970 @default.
• W2911637802 creator A5082706221 @default.
• W2911637802 creator A5090645179 @default.
• W2911637802 date "2019-02-01" @default.
• W2911637802 modified "2023-10-16" @default.
• W2911637802 title "Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC)." @default.
• W2911637802 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.688" @default.
• W2911637802 hasPublicationYear "2019" @default.
• W2911637802 type Work @default.
• W2911637802 sameAs 2911637802 @default.
• W2911637802 citedByCount "14" @default.
• W2911637802 countsByYear W29116378022017 @default.
• W2911637802 countsByYear W29116378022019 @default.
• W2911637802 countsByYear W29116378022020 @default.
• W2911637802 countsByYear W29116378022021 @default.
• W2911637802 crossrefType "journal-article" @default.
• W2911637802 hasAuthorship W2911637802A5000418012 @default.
• W2911637802 hasAuthorship W2911637802A5004259329 @default.
• W2911637802 hasAuthorship W2911637802A5005460328 @default.
• W2911637802 hasAuthorship W2911637802A5015509025 @default.
• W2911637802 hasAuthorship W2911637802A5024390084 @default.
• W2911637802 hasAuthorship W2911637802A5030657436 @default.
• W2911637802 hasAuthorship W2911637802A5038339239 @default.
• W2911637802 hasAuthorship W2911637802A5040469092 @default.
• W2911637802 hasAuthorship W2911637802A5041301470 @default.
• W2911637802 hasAuthorship W2911637802A5043177546 @default.
• W2911637802 hasAuthorship W2911637802A5057458005 @default.
• W2911637802 hasAuthorship W2911637802A5061200817 @default.
• W2911637802 hasAuthorship W2911637802A5062748030 @default.
• W2911637802 hasAuthorship W2911637802A5063738443 @default.
• W2911637802 hasAuthorship W2911637802A5069877747 @default.
• W2911637802 hasAuthorship W2911637802A5072066227 @default.
• W2911637802 hasAuthorship W2911637802A5078038970 @default.
• W2911637802 hasAuthorship W2911637802A5082706221 @default.
• W2911637802 hasAuthorship W2911637802A5090645179 @default.
• W2911637802 hasConcept C121608353 @default.
• W2911637802 hasConcept C126322002 @default.
• W2911637802 hasConcept C143998085 @default.
• W2911637802 hasConcept C197934379 @default.
• W2911637802 hasConcept C2776694085 @default.
• W2911637802 hasConcept C2778332735 @default.
• W2911637802 hasConcept C2778375690 @default.
• W2911637802 hasConcept C2779998722 @default.
• W2911637802 hasConcept C2780259306 @default.
• W2911637802 hasConcept C2780739268 @default.
• W2911637802 hasConcept C526805850 @default.
• W2911637802 hasConcept C71924100 @default.
• W2911637802 hasConceptScore W2911637802C121608353 @default.
• W2911637802 hasConceptScore W2911637802C126322002 @default.
• W2911637802 hasConceptScore W2911637802C143998085 @default.
• W2911637802 hasConceptScore W2911637802C197934379 @default.
• W2911637802 hasConceptScore W2911637802C2776694085 @default.
• W2911637802 hasConceptScore W2911637802C2778332735 @default.
• W2911637802 hasConceptScore W2911637802C2778375690 @default.
• W2911637802 hasConceptScore W2911637802C2779998722 @default.
• W2911637802 hasConceptScore W2911637802C2780259306 @default.
• W2911637802 hasConceptScore W2911637802C2780739268 @default.
• W2911637802 hasConceptScore W2911637802C526805850 @default.
• W2911637802 hasConceptScore W2911637802C71924100 @default.
• W2911637802 hasIssue "4_suppl" @default.
• W2911637802 hasLocation W29116378021 @default.
• W2911637802 hasOpenAccess W2911637802 @default.
• W2911637802 hasPrimaryLocation W29116378021 @default.
• W2911637802 hasRelatedWork W1975647291 @default.
• W2911637802 hasRelatedWork W2152613916 @default.
• W2911637802 hasRelatedWork W2165225928 @default.
• W2911637802 hasRelatedWork W2435704186 @default.
• W2911637802 hasRelatedWork W2508443409 @default.
• W2911637802 hasRelatedWork W2602241548 @default.
• W2911637802 hasRelatedWork W2617055067 @default.
• W2911637802 hasRelatedWork W3000288349 @default.
• W2911637802 hasRelatedWork W3147937635 @default.
• W2911637802 hasRelatedWork W349909140 @default.
• W2911637802 hasVolume "37" @default.
• W2911637802 isParatext "false" @default.
• W2911637802 isRetracted "false" @default.
• W2911637802 magId "2911637802" @default.
• W2911637802 workType "article" @default.